ADG153 is a fully human monoclonal antibody against CD47. ADG153 blocks the CD47/SIRPalpha signaling pathway and becomes activated in protease-rich tumor microenvironments via a cleavable masking peptide. ADG153 induces macrophage phagocytosis, antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), and exhibits antitumor activity in CD47-positive tumor models. ADG153 can be used in research related to myeloid tumors, triple-negative breast cancer and small cell lung cancer.
Target:
CD47
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
